Murielle M Ellison from 645 Camino Manzanas, Thousand Oaks, CA 91360, age 59, Phone: (805)3753857

Us Patents

Fgf21 Mutants And Uses Thereof
view source
US Patent:

8188040, May 29, 2012
Filed:

May 4, 2010
Appl. No.:

12/773266
Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Thousand Oaks CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US
Assignee:

Amgen Inc. - Thousand Oaks CA
International Classification:

A61K 38/18
C07K 14/50
C12N 1/21
C12N 5/10
C12N 15/12
C12N 15/63
US Classification:

514 91, 530350, 530399, 536 235, 4353201, 435325, 435243
Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Uses Of Fgf21 Polypeptides Comprising Two Or More Mutations
view source
US Patent:

8361963, Jan 29, 2013
Filed:

Dec 16, 2011
Appl. No.:

13/328028
Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Newbury Park CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US
Assignee:

Amgen Inc. - Thousand Oaks CA
International Classification:

A61K 38/18
C07K 14/50
US Classification:

514 91, 530350, 530399
Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Fgf21 Mutants And Uses Thereof
view source
US Patent:

8410051, Apr 2, 2013
Filed:

Aug 2, 2011
Appl. No.:

13/196544
Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Newbury Park CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US
Assignee:

Amgen Inc. - Thousand Oaks CA
International Classification:

A61K 38/18
C07K 14/50
C12N 1/21
C12N 5/10
C12N 15/12
C12N 15/63
US Classification:

514 91, 530350, 530399, 536 235, 4353201, 435325, 435243
Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Fgf21 Mutants Multimers And Uses Thereof
view source
US Patent:

8618053, Dec 31, 2013
Filed:

May 3, 2012
Appl. No.:

13/463731
Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Newbury Park CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US
Assignee:

Amgen Inc. - Thousand Oaks CA
International Classification:

A61K 38/18
A61K 39/395
C07K 14/50
C07K 16/00
US Classification:

514 91, 530399, 4241301
Abstract:

The invention provides a multimer comprising at least a first and a second chain, the first chain comprising the polypeptide of SEQ ID NO:4, wherein the leucine at position 98 is substituted with an arginine; the proline at position 171 is substituted with glycine; and the alanine at position 180 is substituted with glutamic acid; a linker sequence comprising SEQ ID NO:31; and an Fe domain comprising SEQ NO:11; and a second chain comprising the polypeptide of SEQ ID NO:4, wherein the leucine at position 98 is substituted with an arginine; the proline at position 171 is substituted with glycine; and the alanine at position 180 is substituted with glutamic acid; a linker sequence comprising SEQ ID NO:31; and an Fe domain comprising SEQ ID NO:11, nucleic acids encoding the multimer, pharmaceutical compositions comprising the multimer and methods for treating metabolic disorders using such nucleic acids, multimers or pharmaceutical compositions.

Fgf21 Mutant Fusion Polypeptides And Uses Thereof
view source
US Patent:

8642546, Feb 4, 2014
Filed:

Dec 15, 2011
Appl. No.:

13/327504
Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Newbury Park CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US
Assignee:

Amgen Inc. - Thousand Oaks CA
International Classification:

A61K 38/18
C07K 14/50
A61K 39/395
C07K 16/00
US Classification:

514 91, 530399, 530350, 5303871
Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant fusion polypeptides comprising mutations at positions 98, 171, 179, 180 or 181, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Fgf21 Mutants And Uses Thereof
view source
US Patent:

20090305986, Dec 10, 2009
Filed:

Jun 3, 2009
Appl. No.:

12/455610
Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Newbury Park CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US
Assignee:

Amgen Inc. - Thousand Oaks CA
International Classification:

C07K 14/00
C07K 17/14
A61K 38/18
C12N 15/11
C12N 15/12
C12N 15/85
C12N 5/06
US Classification:

514 12, 530350, 530402, 530410, 5303911, 536 231, 4353201, 530399, 435325
Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Fgf21 Mutants And Uses Thereof
view source
US Patent:

20110195895, Aug 11, 2011
Filed:

Oct 8, 2009
Appl. No.:

13/123205
Inventors:

Kenneth W. Walker - Newbury Park CA, US
Randy I. Hecht - Thousand Oaks CA, US
Edward J. Belousky - Camarillo CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark L. Michaels - Encino CA, US
Jing Xu - Thousand Oaks CA, US
Murielle M. Ellison - Thousand Oaks CA, US
Assignee:

Amgen Inc. - Thousand Oak
International Classification:

A61K 38/18
C12N 15/63
C12N 1/00
C07H 21/00
C12P 21/02
C07K 14/50
C08F 8/32
C07K 19/00
A61P 3/10
A61P 3/04
A61P 3/00
US Classification:

514 48, 4353201, 435243, 536 235, 435 691, 530399, 525 541, 530397, 514 91, 514 69
Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Fgf21 Mutants And Uses Thereof
view source
US Patent:

20120052069, Mar 1, 2012
Filed:

May 4, 2010
Appl. No.:

13/318756
Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Thousand Oaks CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US
Assignee:

AMGEN INC - Thousand Oaks CA
International Classification:

A61K 39/395
C07K 19/00
A61K 38/18
A61P 3/04
C12N 5/10
A61P 3/10
C12N 15/12
C12N 15/62
C12N 15/85
C07K 14/50
A61P 3/00
US Classification:

4241341, 530399, 5303873, 514 48, 514 69, 514 91, 536 235, 536 234, 4353201, 435328, 435325, 435360
Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.